doravirine, a novel NNRTI, selects for specific mutations in vitro, including mutations at reverse transcriptase (RT) positions 106, 108, 188, 227, 230 and 234. the aim of this study was to examine the prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients.
Soulie, C., Santoro, M.m., Storto, A., Abdi, B., Charpentier, C., Armenia, D., et al. (2020). Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY [10.1093/jac/dkz553].
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy
Santoro, Maria Mercedes;Andreoni, Massimo;Perno, Carlo Federico;Ceccherini-Silberstein, Francesca;
2020-01-24
Abstract
doravirine, a novel NNRTI, selects for specific mutations in vitro, including mutations at reverse transcriptase (RT) positions 106, 108, 188, 227, 230 and 234. the aim of this study was to examine the prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients.File | Dimensione | Formato | |
---|---|---|---|
dkz553.pdf
solo utenti autorizzati
Tipologia:
Versione Editoriale (PDF)
Licenza:
Copyright dell'editore
Dimensione
205.15 kB
Formato
Adobe PDF
|
205.15 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.